Phase II Study of Anti-GD2 3F8 Antibody and Biologic Response Modifiers for High-risk Neuroblastoma
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Beta glucan (Primary) ; Isotretinoin (Primary) ; Monoclonal antibody 3F8 (Primary) ; Sargramostim (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 26 Jun 2008 The expected completion date for this trial is now 1 Nov 2006, as reported by ClinicalTrials.gov
- 25 Aug 2005 New trial record.